Kardigan, Inc. Common Stock (KARD) News
Latest headlines that mention KARD, newest first · each headline opens the original publisher
- Last price
- $12.66
- Day change
- +2.76%
- Next earnings
- —
KARD headlines
latest coverageKardigan (KARD) didn’t just raise $400 million. The heart-drug developer sent a new signal to biotech investors about what Wall Street is willing to fund in 2026. That is not a simple optimism. It’s prejudiced. Biotech businesses might toss around early research, big potential…
Kardigan Inc. shares surged 38% in its trading debut, after the heart-health focused biotech raised $400 million in an initial public offering.
Kardigan Inc. raised $400 million in an upsized US initial public offering that priced at the top of its marketed range.
Kardigan Inc. is seeking to raise $373.3 million in a US initial public offering to help fund three late-stage drugs that target cardiovascular diseases.
Kardigan Inc. filed for a US initial public offering that will help fund three late-stage drugs that target the root cause of cardiovascular diseases.
KARD news alerts
Get an alert by email or push when a new headline mentions KARD.
More news
News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.